Know Cancer

forgot password

Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II

Phase 2
15 Years
70 Years
Open (Enrolling)

Thank you

Trial Information

Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II


- Determine the 2-year progression-free survival of patients with progressive or
recurrent Hodgkin's lymphoma treated with tandem autologous stem cell transplantation
(2 courses of high-dose therapy with autologous stem cell rescue).

- Determine the response rate in patients treated with this regimen.

- Determine the toxic effects of this regimen in these patients.

OUTLINE: This is a multicenter study.

- Salvage therapy (for patients with relapsed disease after achieving a previous complete
response): Patients receive at least 2 courses of salvage chemotherapy or radiotherapy.
No more than 6 weeks later, patients proceed to autologous hematopoietic stem cell

- Autologous hematopoietic stem cell collection: Patients undergo autologous
hematopoietic stem cell collection. Patients with an inadequate number of collected
stem cells are removed from the study.

- Pre-transplant salvage radiation: Patients with residual tumor greater than 5 cm after
initial salvage therapy undergo involved-field radiotherapy. All patients then proceed
to the first preparative regimen.

- First preparative regimen: Patients receive high-dose melphalan IV on day -1.

- First autologous stem cell transplantation (SCT): Patients undergo autologous SCT on
day 0. At least 28 days later, patients proceed to second preparative regimen.

- Second preparative regimen: Patients receive 1 of the following preparative regimens:

- Total-body irradiation (TBI)-based regimen: Patients undergo TBI twice daily on
days -8 to -5. Patients also receive etoposide IV over 4 hours on day -4 and
cyclophosphamide IV over 1 hour on day -2.

- Carmustine-based regimen: Patients receive carmustine IV over 2 hours on days -6
to -4, etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on
day -2.

- Second autologous SCT: Patients undergo second autologous SCT on day 0. After
completion of study treatment, patients are followed every 6 months for 2 years and
then annually for up to 7 years.

PROJECTED ACCRUAL: A total of 85 patients will be accrued for this study over 2 years.

Inclusion Criteria


- Histologically or cytologically confirmed Hodgkin's lymphoma

- Relapsed or refractory disease

- Biopsy or radiological evidence of disease at time of recurrence/progression

- Has received ≥ 1 prior systemic chemotherapy regimen

- No clonal abnormalities in marrow collection

- Must undergo involved-field radiotherapy if bulky disease > 5 cm

- Must have adequate sections of original diagnostic specimen available for review

- Needle aspirations or cytologies are not adequate

- No prior lymphoma, myelodysplastic syndromes, or leukemia (even if disease free > 5

- Patients who relapse after achieving a complete remission must complete a minimum of
2 courses of salvage chemotherapy or radiation therapy to determine if sensitive or
resistant recurrent disease is present

- No central nervous system (CNS) involvement



- 15 to 70

Performance status

- Zubrod 0-2

Life expectancy

- Not specified


- Absolute neutrophil count ≥ 1,500/mm^3


- Bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless due to Hodgkin's disease)


- Creatinine clearance ≥ 60 mL/min

- Creatinine ≤ 2 times upper limit of normal


- None of the following conditions requiring therapy:

- Coronary artery disease

- Cardiomyopathy

- Congestive heart failure

- Arrhythmias

- Ejection fraction ≥ 45% by Multi Gated Acquisition Scan (MUGA) or 2-D echocardiogram


- Adequate pulmonary function

- Corrected diffusing capacity of lung for carbon monoxide (DLCO) ≥ 60% OR

- Forced Expiratory Volume in One Side (FEV_1) ≥ 60% of predicted


- Not pregnant or nursing

- Fertile patients must use effective contraception

- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer

- No known HIV or AIDS infection

- No active bacterial, fungal, or viral infection

- No medical condition that would preclude study treatment


Biologic therapy

- Not specified


- See Disease Characteristics

Endocrine therapy

- Not specified


- See Disease Characteristics


- Not specified

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

2-year Progression-free Survival

Outcome Description:

Measured from date of randomization to date of first observation of progressive disease, or death due to any cause

Outcome Time Frame:

At day 60, then every 6 months for 2 years

Safety Issue:


Principal Investigator

Eileen P. Smith, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Beckman Research Institute


United States: Federal Government

Study ID:




Start Date:

October 2005

Completion Date:

February 2016

Related Keywords:

  • Lymphoma
  • recurrent adult Hodgkin lymphoma
  • Hodgkin Disease
  • Lymphoma



Fred Hutchinson Cancer Research Center Seattle, Washington  98109
Cardinal Bernardin Cancer Center at Loyola University Medical Center Maywood, Illinois  60153-5500
CCOP - Wichita Wichita, Kansas  67214-3882
CCOP - Columbia River Oncology Program Portland, Oregon  97225
MultiCare Regional Cancer Center at Tacoma General Hospital Tacoma, Washington  98405
CCOP - Northwest Tacoma, Washington  98405-0986
University of California Davis Cancer Center Sacramento, California  95817
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus Seattle, Washington  98104
Thompson Cancer Survival Center Knoxville, Tennessee  37916
Via Christi Cancer Center at Via Christi Regional Medical Center Wichita, Kansas  67214
Southwest Medical Center Liberal, Kansas  67901
Olympic Hematology and Oncology Bremerton, Washington  98310
University Cancer Center at University of Washington Medical Center Seattle, Washington  98195
Harborview Medical Center Seattle, Washington  98104
Group Health Central Hospital Seattle, Washington  98104
Cancer Care Northwest - Spokane South Spokane, Washington  99202
Mountain States Tumor Institute at St. Luke's Regional Medical Center Boise, Idaho  83712-6297
Tulane Cancer Center Office of Clinical Research Alexandria, Louisiana  71315-3198
Legacy Emanuel Hospital and Health Center and Children's Hospital Portland, Oregon  97227
Cancer Center of Kansas, PA - Dodge City Dodge City, Kansas  67801
Legacy Mount Hood Medical Center Gresham, Oregon  97030
Providence Milwaukie Hospital Milwaukie, Oregon  97222
Providence Cancer Center at Providence Portland Medical Center Portland, Oregon  97213-2967
Providence St. Vincent Medical Center Portland, Oregon  97225
Legacy Meridian Park Hospital Tualatin, Oregon  97062
Minor and James Medical, PLLC Seattle, Washington  98104
Polyclinic First Hill Seattle, Washington  98122
Southwest Washington Medical Center Cancer Center Vancouver, Washington  98668
St. Francis Hospital Federal Way, Washington  98003
St. Clare Hospital Lakewood, Washington  98499-0998
Providence St. Peter Hospital Regional Cancer Center Olympia, Washington  98506
Good Samaritan Cancer Center Puyallup, Washington  98371
Allenmore Hospital Tacoma, Washington  98411-0414
Cancer Center of Kansas, PA - Chanute Chanute, Kansas  66720
Cancer Center of Kansas, PA - El Dorado El Dorado, Kansas  67042
Cancer Center of Kansas-Independence Independence, Kansas  67301
Cancer Center of Kansas, PA - Kingman Kingman, Kansas  67068
Cancer Center of Kansas, PA - Newton Newton, Kansas  67114
Cancer Center of Kansas, PA - Parsons Parsons, Kansas  67357
Cancer Center of Kansas, PA - Pratt Pratt, Kansas  67124
Cancer Center of Kansas, PA - Salina Salina, Kansas  67401
Cancer Center of Kansas, PA - Wellington Wellington, Kansas  67152
Cancer Center of Kansas, PA - Wichita Wichita, Kansas  67214
Associates in Womens Health, PA - North Review Wichita, Kansas  67208
Cancer Center of Kansas, PA - Medical Arts Tower Wichita, Kansas  67208
Cancer Center of Kansas, PA - Winfield Winfield, Kansas  67156
Adventist Medical Center Portland, Oregon  97216
Legacy Good Samaritan Hospital & Comprehensive Cancer Center Portland, Oregon  97210
St. Joseph Cancer Center Bellingham, Washington  98225
Providence Centralia Hospital Centralia, Washington  98531-9027
Columbia Basin Hematology Kennewick, Washington  99336
Franciscan Cancer Center at St. Joseph Medical Center Tacoma, Washington  98405-3004
Auburn Regional Center for Cancer Care Auburn, Washington  98002